Updated:
NewLink Genetics Corporation
NewLink Genetics was founded to advance immunotherapeutic approaches to oncology, building on decades of research into how tumors evade immune detection.
NewLink Genetics Corporation
NewLink Genetics was founded to advance immunotherapeutic approaches to oncology, building on decades of research into how tumors evade immune detection. The company operates as a publicly traded entity (Nasdaq: NLNK) and has historically focused on two core platforms: HyperAcute immunotherapy, which uses modified allogeneic tumor cells engineered to express alpha-gal epitopes, and small-molecule inhibitors of the IDO pathway, an immune checkpoint mechanism. The firm's pipeline has included clinical trials for pancreatic cancer, melanoma, and other solid tumors. The company's strategy has involved internally developed candidates and academic collaborations. NewLink has conducted multiple Phase 2 and Phase 3 clinical trials, including the IMPRESS trial for algenpantucel-L in pancreatic cancer and Phase 2 studies of indoximod in combination with checkpoint inhibitors for melanoma (per clinicaltrials.gov records). The firm has also investigated compounds targeting T-cell metabolism and tumor microenvironment modulation. Geographically, operations are based in Ames, Iowa, with clinical trial sites across the United States. NewLink has disclosed minimal current public financial details, and its clinical-stage status means it has not generated commercial product revenue. As of recent filings, the company's market capitalization was in the tens of millions. No team size, additional offices, or adjacent philanthropic vehicles are publicly specified. The firm's most notable recent operational event was a September 2023 announcement regarding a strategic restructuring and reduction in workforce as it reassessed its pipeline priorities (per SEC filing). What distinguishes NewLink Genetics is its focus on two differentiated immunotherapy platforms — HyperAcute cellular vaccines and IDO pathway modulation — which are distinct from the checkpoint inhibitor and CAR-T approaches that dominate the field. This specialization, while narrowing its market, positions the firm as a pure-play developer of mechanism-validated adjunctive immunotherapies. The company's academic roots and Iowa base contrast with the Boston/San Francisco biotech concentration, reflecting a deliberate operational strategy.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Ames
Corporate office
Ames, IA, United States
Sector focus
Frequently asked questions
What is NewLink Genetics' primary therapeutic focus?
NewLink Genetics develops immunotherapies for cancer, specifically using two platforms: HyperAcute immunotherapy (allogeneic tumor cell vaccines engineered with alpha-gal epitopes) and small-molecule IDO pathway inhibitors like indoximod. Its lead programs target pancreatic cancer and melanoma (per clinicaltrials.gov).
Is NewLink Genetics publicly traded or privately held?
NewLink Genetics is publicly traded on the Nasdaq under the ticker NLNK. It operates as a corporation with public shareholders, unlike a private family office. The company's financial disclosures are filed with the SEC.
What stage of clinical development are NewLink's lead candidates in?
NewLink's lead biologic candidate, algenpantucel-L (HyperAcute-Pancreas), completed a Phase 3 trial for pancreatic cancer, though the trial did not meet its primary endpoint in 2016 (per the firm's public disclosures). The IDO inhibitor indoximod has been studied in Phase 2 trials for melanoma in combination with checkpoint inhibitors (per clinicaltrials.gov).
How does NewLink's technology differ from checkpoint inhibitors or CAR-T therapies?
NewLink's HyperAcute platform uses modified whole tumor cells to prime the immune system against tumor-specific antigens, rather than blocking immune checkpoints (e.g., PD-1) or engineering T-cells. Its IDO inhibitors target a metabolic immune checkpoint distinct from standard checkpoint blockade, potentially offering complementary mechanisms (per the firm's scientific publications).
Where is NewLink Genetics based and what is its operational footprint?
The company is headquartered in Ames, Iowa, with clinical trial operations across the U.S. It does not publicly disclose additional offices outside of its Iowa base.
Has Newlink Genetics generated any revenue from commercial products?
No. As a clinical-stage biotechnology company, NewLink Genetics has not generated revenue from product sales. Its funding has come from public equity offerings, private placements, and collaboration agreements (per SEC filings).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: